CA-SRIJAN/MATERIAL
Srijan, the technology and engineering division for Material, a global strategy and customer experience transformation consultancy, is proud to announce it has been named a 2023 Acquia Engage Award winner for its work with INSEAD - The Business School for the World® in the Most Impactful Tech Stack Integration category.
The Acquia Engage Awards recognize organizations that go above and beyond to craft and deliver outstanding digital experiences leveraging the Acquia Open Digital Experience Platform (Acquia Open DXP).
Srijan partnered with INSEAD to revolutionize its digital strategy, improve user engagement, and strengthen its brand identity by building an agile, efficient, and unified digital platform, aligning technology with business strategy to drive growth and success. By utilizing third-party integrations and CDP implementation, Srijan streamlined user journeys with an engaging, cohesive, and effective digital presence.
“INSEAD's success with our tailored solution approach truly exemplifies our commitment to excellence and value,” said Saurabh Das, Chief Delivery Officer for Material. “Being recognized with this award is a testament of our team's relentless focus on delivering impactful solutions that provide unprecedented value for our customers.”
“I appreciate very much the strategic partnership we have with Srijan. It was a very challenging project and Srijan has proven to be a trusted partner, working closely with us in navigating and resolving problems – not only from a technical standpoint but also on a stakeholders management front,” said Choo Tatt Saw, CIO for INSEAD.
Dov Campbell, Director Digital Communications for INSEAD, added: “Our strong collaboration with Srijan enabled us to create a robust, adaptable and seamlessly integrated website that remains true to our initial vision.”
“Our partnership with INSEAD has been dynamic and engaging, where each milestone was met with tailored solutions and a shared commitment to excellence. This award is a testament to that agile and collaborative spirit,” said Rupa Mistry, Delivery Director for Material.
This year’s Engage Awards received hundreds of entries spanning a variety of industries and regions in 26 categories. Each submission was presented to a panel of respected digital experts, who evaluated them on functionality, integration, performance, results, overall user experience, and other criteria. Learn more about how Srijan leveraged Acquia and other tech stacks with the case study here.
About Srijan, A Material Company
Srijan, a Material company, is a global engineering firm that builds transformative digital paths to better futures for a wide range of businesses, from Fortune 500 enterprises to nonprofits worldwide. We bring advanced engineering capabilities and agile practices to some of the biggest names across FMCG, aviation, telecom, technology, and others. Srijan is a Drupal Enterprise Partner & Diamond Certified Contributor and Drupal leader, with 350+ Drupal engineers, and 110+ Acquia certifications.
In 2021, Srijan was acquired by Material, a global strategy partner that combines deep human insights with modern technology – a proprietary science + systems approach that speeds engagement and growth for the world’s most recognizable brands and innovative companies. We design and build customer-centric business models and experiences to create transformative relationships between businesses and the people they serve. For more information visit https://www.materialplus.io/.
About Acquia
Acquia empowers ambitious digital innovators to craft the most productive, frictionless digital experiences that make a difference to their customers, employees, and communities. We provide the world's leading open digital experience platform (DXP), built on open source Drupal, as part of our commitment to shaping a digital future that is safe, accessible, and available to all. With Acquia Open DXP, you can unlock the potential of your customer data and content, accelerating time to market and increasing engagement, conversion, and revenue. Learn more at https://acquia.com.
About INSEAD, The Business School for the World
As one of the world’s leading and largest graduate business schools, INSEAD brings together people, cultures and ideas to develop responsible leaders who transform business and society. Our research, teaching and partnerships reflect this global perspective and cultural diversity.
With locations in Europe (France), Asia (Singapore), the Middle East (Abu Dhabi), and now North America (San Francisco), INSEAD's business education and research spans four regions.
Our 162 renowned Faculty members from 40 countries inspire more than 1,300 degree participants annually in our Master in Management, MBA, Global Executive MBA, Specialized Master’s degrees (Executive Master in Finance and Executive Master in Change) and PhD programmes. In addition, more than 10,000 executives participate in INSEAD Executive Education programmes each year.
INSEAD continues to conduct cutting-edge research and innovate across all our programmes. We provide business leaders with the knowledge and awareness to operate anywhere. Our core values drive academic excellence and serve the global community as The Business School for the World.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231115640758/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom